Magnesium

FIRST COAST SERVICE OPTIONS
MAC - PART A/B
LOCAL COVERAGE DETERMINATION

LCD Database ID Number
L34014

Contractor Name
First Coast Service Options, Inc.

Contractor Number
09101 - Florida
09201 – Puerto Rico/Virgin Islands
09102 – Florida
09202 – Puerto Rico
09302 – Virgin Islands

Contractor Type
MAC – Part A and B

LCD Title
Magnesium

AMA CPT Copyright Statement
CPT only copyright 2002-2017 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. Applicable FARS/DFARS Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. The Code on Dental Procedures and Nomenclature (Code) is published in Current Dental Terminology (CDT). Copyright (c) American Dental Association. All rights reserved. CDT and CDT-2010 are trademarks of the American Dental Association.

CMS National Coverage Policy
Language quoted from CMS National Coverage Determinations (NCDs) and coverage provisions in interpretive manuals are italicized throughout the Local Coverage Determination (LCD). NCDs and coverage provisions in interpretive manuals are not subject to the LCD Review Process (42 CFR 405.860[b] and 42 CFR 426 [Subpart D]). In addition, an administrative law judge may not review an NCD. See §1869(f)(1)(A)(i) of the Social Security Act.

Unless otherwise specified, italicized text represents quotation from one or more of the following CMS sources:

CMS Manual System, Pub. 100-04, Chapter 8, Section 50.1
Indications and Limitations of Coverage and/or Medical Necessity

Magnesium is an important activator ion, participating in the function of many enzymes involved in phosphate transfer reactions. Most of the magnesium found within the body exists intracellularly, and since most of it is bound to adenosine triphosphate, this electrolyte is critical in nearly all metabolic processes and most organ functions. Magnesium exerts physiologic effects on the nervous system resembling those of calcium, acting directly upon the myoneural junction. Furthermore, magnesium acts as a cofactor that modifies the activity of many enzymes. Carbohydrate, protein, and nucleic acid metabolism depend on magnesium. Excretion of magnesium is via the kidney, and altered concentration of magnesium in the plasma usually provokes an associated alteration of calcium and potassium. The normal plasma concentration of magnesium is 1.5-2.5 meq/L, with about one-third bound to protein and two-thirds existing as free cation.

Magnesium testing will be considered medically necessary under any of the following circumstances:

- In the presence of signs or symptoms of hypomagnesemia, which include weakness, muscle cramping, irritability, tetany, electrocardiographic changes, delirium, anorexia, nausea, and vomiting. Conditions which can produce these signs and symptoms include, but are not limited to the following:
  - cardiac arrhythmias
  - malabsorption syndromes
  - alcoholism
  - parenteral alimentation with inadequate magnesium content
  - diarrhea
  - diabetic ketoacidosis
  - diuretic therapy
  - hyperaldosteronism
  - hypoparathyroidism
  - hyperthyroidism
  - chronic renal disease
  - prolonged I.V. therapy
Magnesium

- prolonged nasogastric suction
- cisplatinum therapy
- aminoglycoside toxicity
- amphotericin toxicity

- In the presence of signs or symptoms of hypermagnesemia, including muscle weakness, mental obtundation, and confusion. Weakness and a fall in blood pressure are evident on examination. There may be respiratory muscle paralysis or cardiac arrest. Conditions which can produce these signs and symptoms include, but are not limited to the following:
  - adrenal insufficiency
  - renal insufficiency
  - ingestion of magnesium-containing drugs, such as antacids and laxatives
  - rhabdomyolysis

**Type of Bill Code**

Hospital: 12x, 13x, 14x
Skilled Nursing Facility - 21x, 22x, 23x
End Stage Renal Disease – 72x
Critical Access Hospital – 85x

**Revenue Codes**

301 Laboratory, Chemistry

**CPT/HCPCS Codes**

83735 Magnesium

**ICD-10 Codes that Support Medical Necessity**

B25.2 Cytomegaloviral pancreatitis
E03.5 Myxedema coma
E05.00-E05.91 Thyrotoxicosis [hyperthyroidism]
E10.10 Type 1 diabetes mellitus with ketoacidosis without coma
E10.11 Type 1 diabetes mellitus with ketoacidosis with coma
E10.311-E10.39 Type 1 diabetes mellitus with ophthalmic complications
E10.40-E10.49 Type 1 diabetes mellitus with neurological complications
E10.51-E10.59 Type 1 diabetes mellitus with circulatory complications
E10.610 Type 1 diabetes mellitus with diabetic neuropathic arthropathy
E10.618-E10.638 Type 1 diabetes mellitus with other specified complications
E10.649-E10.69 Type 1 diabetes mellitus with other specified complications
E11.00-E11.01 Type 2 diabetes mellitus with hyperosmolarity
E11.10 – E11.11 Type 2 diabetes mellitus with ketoacidosis without coma - Type 2 diabetes mellitus with ketoacidosis with coma
E11.21-E11.29 Type 2 diabetes mellitus with kidney complications
E11.311-E11.39 Type 2 diabetes mellitus with ophthalmic complications
E11.40-E11.49 Type 2 diabetes mellitus with neurological complications
E11.51-E11.59 Type 2 diabetes mellitus with circulatory complications
E11.610 Type 2 diabetes mellitus with diabetic neuropathic arthropathy
E11.618-E11.638 Type 2 diabetes mellitus with other specified complications
E11.641 Type 2 diabetes mellitus with hypoglycemia with coma
E11.649-E11.69 Type 2 diabetes mellitus with other specified complications
E13.00-E13.01 Other specified diabetes mellitus with hyperosmolarity
E13.10 Other specified diabetes mellitus with ketoacidosis without coma
E13.11 Other specified diabetes mellitus with ketoacidosis with coma
E13.21-E13.29 Other specified diabetes mellitus with kidney complications
E13.31-E13.39 Other specified diabetes mellitus with ophthalmic complications
E13.40-E13.49 Other specified diabetes mellitus with neurological complications
E13.51-E13.59 Other specified diabetes mellitus with circulatory complications
E13.610 Other specified diabetes mellitus with diabetic neuropathic arthropathy
E13.618-E13.638 Other specified diabetes mellitus with other specified complications
E13.641 Other specified diabetes mellitus with hypoglycemia with coma
E13.649-E13.69 Other specified diabetes mellitus with other specified complications
E20.0 Idiopathic hypoparathyroidism
E20.1 Pseudohypoparathyroidism
E20.8-E20.9 Hypoparathyroidism
E21.0-E21.3 Hyperparathyroidism and other disorders of parathyroid gland
E21.4 Other specified disorders of parathyroid gland
E22.2 Syndrome of inappropriate secretion of antidiuretic hormone
E26.01-E26.9 Hyperaldosteronism
E27.1-E27.49 Other disorders of adrenal gland
E34.2 Ectopic hormone secretion, not elsewhere classified
E40 Kwashiorkor
E41 Nutritional marasmus
E42 Marasmic kwashiorkor
E43 Unspecified severe protein-calorie malnutrition
E44.0 Moderate protein-calorie malnutrition
E46 Unspecified protein-calorie malnutrition
E79.0 Hyperuricemia without signs of inflammatory arthritis and tophaceous disease
E83.40 Disorders of magnesium metabolism, unspecified
E83.41 Hypermagnesemia
E83.42 Hypomagnesemia
E83.49 Other disorders of magnesium metabolism
E87.2 Acidosis
E83.50-E83.59 Disorders of calcium metabolism
E86.0 Dehydration
E86.1 Hypovolemia
E86.9 Volume depletion, unspecified
E87.4 Mixed disorder of acid-base balance
E87.5 Hyperkalemia
E87.6 Hypokalemia
E89.2 Postprocedural hypoparathyroidism
E89.6 Postprocedural adrenocortical (-medullary) hypofunction
F05 Delirium due to known physiological condition
F10.10-F10.120 Alcohol abuse
F10.129 Alcohol abuse with intoxication, unspecified
F10.20-F10.21 Alcohol dependence
F50.00-F50.02 Anorexia nervosa
F50.2 Bulimia nervosa
F98.3 Pica of infancy and childhood
G25.3 Myoclonus
G25.61-G25.69 Drug induced tics and other tics of organic origin
I21.01-I22.9 Diseases of the circulatory system system
I34.0-I34.9 Nonrheumatic mitral valve disorders
I46.2-I49.8 Other forms of heart disease
I50.20-I50.9 Heart failure
Magnesium.3 A/B

I95.0-I95.89 Hypotension
I97.110-I97.191 Other postprocedural cardiac functional disturbances
I97.710-I97.791 Intraoperative cardiac functional disturbances
I97.88-I97.89 Other intraoperative and postprocedural complications and disorders of the circulatory system, not elsewhere classified
K52.21-K52.29 Allergic and dietetic gastroenteritis and colitis
K52.831- K52.839 Microscopic colitis
K52.89 Other specified noninfective gastroenteritis and colitis
K85.00-K87 Disorders of gallbladder, biliary tract and pancreas
K91.2 Postsurgical malabsorption, not elsewhere classified
M35.4 Diffuse (eosinophilic) fasciitis
M62.20-M62.28 Nontraumatic ischemic infarction of muscle
M62.81 Muscle weakness (generalized)
M62.82 Rhabdomyolysis
M62.84 Sarcopenia
M62.89 Other specified disorders of muscle
M72.8 Other fibroblastic disorders
N17.0-N17.9 Acute kidney failure
N18.1-N18.9 Chronic kidney disease (CKD)
N25.81-N25.89 Other disorders resulting from impaired renal tubular function
N28.0 Ischemia and infarction of kidney
O21.0-O21.8 Excessive vomiting in pregnancy
O26.10-O26.13 Low weight gain in pregnancy
O26.30-O26.43 Maternal care for other conditions predominantly related to pregnancy
O26.63-O26.819 Maternal care for other conditions predominantly related to pregnancy
O26.86 Pruritic urticarial papules and plaques of pregnancy (PUPPP)
O26.891-O26.899 Other specified pregnancy related conditions
O26.91-O26.93 Pregnancy related conditions, unspecified
O29.011-O29.93 Complications of anesthesia during pregnancy
O90.89 Other complications of the puerperium, not elsewhere classified
O99.89 Other specified diseases and conditions complicating pregnancy, childbirth and the puerperium
P03.810-P03.89 Newborn (suspected to be) affected by other specified complications of labor and delivery
R00.0 Tachycardia, unspecified
R00.1 Bradycardia, unspecified
R11.0-R11.12 Nausea and vomiting
R11.14-R11.2 Nausea and vomiting
R11.13 Vomiting of fecal matter
R19.7 Diarrhea, unspecified
R25.0-R25.9 Abnormal involuntary movements
R29.0 Tetany
R29.2 Abnormal reflex
R40.0-R40.1 Somnolence, stupor and coma
R40.20-R40.2124 Coma
R40.2210-R40.2224 Coma scale, best verbal response
R40.2310-R40.2324 Coma scale, best motor response
R40.2340-R40.2344 Coma scale, best motor response, flexion withdrawal
R40.4 Transient alteration of awareness
R55 Syncope and collapse
Magnesium.3 A/B

R56.00-R56.9  Convulsions, not elsewhere classified
R57.0-R57.9  Shock, not elsewhere classified
R63.0  Anorexia
R64  Cachexia
R65.21  Severe sepsis with septic shock
R78.71-R78.79  Finding of abnormal level of heavy metals in blood
R78.89  Finding of other specified substances, not normally found in blood
R79.0  Abnormal level of blood mineral
R79.89-R79.9  Other abnormal findings of blood chemistry
R94.31  Abnormal electrocardiogram [ECG] [EKG]
R94.4  Abnormal results of kidney function studies
T20.00XA-T25.799  Burns and corrosions of external body surface, specified by site
T26.00XA-T28.99XS  Burn and corrosion confined to eye and adnexa
T36.0X5A-S  Adverse effect of penicillins, initial encounter
T36.1X5A-S  Adverse effect of cephalosporins and other beta-lactam antibiotics, initial encounter
T36.2X5A-S  Adverse effect of chloramphenicol group, initial encounter
T36.3X5A-S  Adverse effect of macrolides, initial encounter
T36.4X5A-S  Adverse effect of tetracyclines, initial encounter
T36.5X5A-S  Adverse effect of aminoglycosides, initial encounter Corrosion of other parts of alimentary tract, initial encounter
T36.6X5A-S  Adverse effect of rifampicins, initial encounter
T36.7X5A-S  Adverse effect of antifungal antibiotics, systemically used, initial encounter
T36.8X5A-S  Adverse effect of other systemic antibiotics, initial encounter
T36.9X5A-S  Adverse effect of unspecified systemic antibiotic, initial encounter
T37.0X5A-S  Adverse effect of sulfonamides, initial encounter
T37.1X5A-S  Adverse effect of antimycobacterial drugs, initial encounter
T37.2X5A-S  Adverse effect of antimalarials and drugs acting on other blood protozoa, initial encounter
T37.3X5A-S  Adverse effect of other antiprotozoal drugs, initial encounter
T37.4X5A-S  Adverse effect of anthelminthics, initial encounter
T37.5X5A-S  Adverse effect of antiviral drugs, initial encounter
T37.6X5A-S  Adverse effect of other antiprotozoal drugs, initial encounter
T37.8X5A-S  Adverse effect of other specified systemic anti-infectives and antiparasitics, initial encounter
T37.95XA-S  Adverse effect of unspecified systemic anti-infective and antiparasitic, initial encounter
T38.0X5A-S  Adverse effect of glucocorticoids and synthetic analogues, initial encounter
T38.1X5A-S  Adverse effect of thyroid hormones and substitutes, initial encounter
T38.2X5A-S  Adverse effect of antithyroid drugs, initial encounter
T38.3X5A-S  Adverse effect of oral contraceptives, initial encounter
T38.5X5A-S  Adverse effect of estrogen drugs and progestogens, initial encounter
T38.6X5A-S  Adverse effect of anticonvulsants, antihormones, not elsewhere classified, initial encounter
T38.7X5A-S  Adverse effect of androgens and anabolic congeners, initial encounter
T38.805A-S  Adverse effect of unspecified hormones and synthetic substitutes, initial encounter
T38.815A-S  Adverse effect of anterior pituitary [adenohypophyseal] hormones, initial encounter
T38.895A-S  Adverse effect of other hormones and synthetic substitutes, initial encounter
T38.905A-S  Adverse effect of unspecified hormone antagonists, initial encounter
T38.995A-S  Adverse effect of other hormone antagonists, initial encounter
T39.015A-S  Adverse effect of aspirin, initial encounter
T39.095A-S  Adverse effect of salicylates, initial encounter
T39.1X5A-S  Adverse effect of 4-Aminophenol derivatives, initial encounter
T39.2X5A-S  Adverse effect of pyrazolone derivatives, initial encounter
T39.315A-S  Adverse effect of propionic acid derivatives, initial encounter
T39.395A-S  Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], initial encounter
T39.4X5A-S  Adverse effect of antirheumatics, not elsewhere classified, initial encounter
T39.8X5A-S  Adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, initial encounter
T39.95XA-S  Adverse effect of unspecified nonopioid analgesic, antipyretic and antirheumatic, initial encounter
T40.0X5A-S  Adverse effect of opium, initial encounter
T40.2X5A-S  Adverse effect of other opioids, initial encounter
T40.3X5A-S  Adverse effect of methadone, initial encounter
T40.4X5A-S  Adverse effect of other synthetic narcotics, initial encounter
T40.5X5A-S  Adverse effect of cocaine, initial encounter
T40.605A-S  Adverse effect of unspecified narcotics, initial encounter
T40.695A-S  Adverse effect of other narcotics, initial encounter
T40.7X5A-S  Adverse effect of cannabis (derivatives), initial encounter
T40.905A-S  Adverse effect of unspecified psychodysleptics [hallucinogens], initial encounter
T40.995A-S  Adverse effect of other psychodysleptics [hallucinogens], initial encounter
T41.5X5A-S  Adverse effect of therapeutic gases, initial encounter
T42.0X5A-S  Adverse effect of hydantoin derivatives, initial encounter
T42.1X5A-S  Adverse effect of iminostilbenes, initial encounter
T42.2X5A-S  Adverse effect of succinimides and oxazolidinediones, initial encounter
T42.3X5A-S  Adverse effect of barbiturates, initial encounter
T42.4X5A-S  Adverse effect of benzodiazepines, initial encounter
T42.5X5A-S  Adverse effect of mixed antiepileptics, initial encounter
T42.6X5A-S  Adverse effect of other antiepileptic and sedative-hypnotic drugs, initial encounter
T42.75XA-S  Adverse effect of unspecified antiepileptic and sedative-hypnotic drugs, initial encounter
T42.8X5A-S  Adverse effect of antiparkinsonism drugs and other central muscle-tone depressants, initial encounter
T43.015A-S  Adverse effect of tricyclic antidepressants, initial encounter
T43.025A-S  Adverse effect of tetracyclic antidepressants, initial encounter
T43.1X5A-S  Adverse effect of monoamine-oxidase-inhibitor antidepressants, initial encounter
T43.205A-S  Adverse effect of unspecified antidepressants, initial encounter
T43.215A-S  Adverse effect of selective serotonin and norepinephrine reuptake inhibitors, initial encounter
T43.225A-S  Adverse effect of selective serotonin reuptake inhibitors, initial encounter
T43.295A-S  Adverse effect of other antidepressants, initial encounter
T43.3X5A-S  Adverse effect of phenothiazine antipsychotics and neuroleptics, initial encounter
T43.4X5A-S  Adverse effect of butyrophenone and thiothixene neuroleptics, initial encounter
T43.505A-S  Adverse effect of unspecified antipsychotics and neuroleptics, initial encounter
T43.595A-S  Adverse effect of other antipsychotics and neuroleptics, initial encounter
T43.605A-S  Adverse effect of unspecified psychostimulants, initial encounter
T43.615A-S  Adverse effect of caffeine, initial encounter
T43.625A-S  Adverse effect of amphetamines, initial encounter
T43.635A-S  Adverse effect of methylphenidate, initial encounter
T43.695A-S  Adverse effect of other psychostimulants, initial encounter
T43.8X5A-S  Adverse effect of other psychotropic drugs, initial encounter
T43.95XA-S  Adverse effect of unspecified psychotropic drug, initial encounter
T44.0X5A-S  Adverse effect of anticholinesterase agents, initial encounter
T44.1X5A-S  Adverse effect of other parasymptathomimetics [cholinergics], initial encounter
T44.2X5A-S  Adverse effect of ganglionic blocking drugs, initial encounter
T44.3X5A-S  Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmodics, initial encounter
T44.4X5A-S  Adverse effect of predominantly alpha-adrenoreceptor agonists, initial encounter
T44.5X5A-S  Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter
T44.6X5A-S  Adverse effect of alpha-adrenoreceptor antagonists, initial encounter
T44.7X5A-S  Adverse effect of beta-adrenoreceptor antagonists, initial encounter
T44.8X5A-S  Adverse effect of centrally-acting and adrenergic-neuron-blocking agents, initial encounter
T44.905A-S  Adverse effect of unspecified drugs primarily affecting the autonomic nervous system, initial encounter
T44.995A-S  Adverse effect of other drug primarily affecting the autonomic nervous system, initial encounter
T45.0X5A-S  Adverse effect of antiallergic and antiinflammatory drugs, initial encounter
T45.1X5A-S  Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter
T45.2X5A-S  Adverse effect of vitamins, initial encounter
T45.3X5A-S  Adverse effect of enzymes, initial encounter
T45.4X5A-S  Adverse effect of iron and its compounds, initial encounter
T45.6X5A-S  Adverse effect of anticoagulants, initial encounter
T45.7X5A-S  Adverse effect of thrombolytic drugs, initial encounter
T45.8X5A-S  Adverse effect of anticoagulant antagonists, vitamin K and other coagulants, initial encounter
T45.95X5A-S  Adverse effect of other primarily systemic and hematological agents, initial encounter
T46.0X5A-S  Adverse effect of histamine H2-receptor blockers, initial encounter
T46.1X5A-S  Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter
T46.2X5A-S  Adverse effect of stimulant laxatives, initial encounter
T46.3X5A-S  Adverse effect of saline and osmotic laxatives, initial encounter
T46.4X5A-S  Adverse effect of anti-diarrheal drugs, initial encounter
T46.5X5A-S  Adverse effect of emetics, initial encounter
T46.6X5A-S  Adverse effect of digestants, initial encounter
T46.7X5A-S  Adverse effect of antidiarrheal drugs, initial encounter
T47.95XA-S Adverse effect of unspecified agents primarily affecting the gastrointestinal system, initial encounter
T48.0X5A-S Adverse effect of oxytocic drugs, initial encounter
T48.1X5A-S Adverse effect of skeletal muscle relaxants [neuromuscular blocking agents], initial encounter
T48.205A-S Adverse effect of unspecified drugs acting on muscles, initial encounter
T48.295A-S Adverse effect of other drugs acting on muscles, initial encounter
T48.3X5A-S Adverse effect of antitussives, initial encounter
T48.4X5A-S Adverse effect of skeletal muscle relaxants [neuromuscular blocking agents], initial encounter
T48.5X5A-S Adverse effect of other anti-common-cold drugs, initial encounter
T48.6X5A-S Adverse effect of antiasthmatics, initial encounter
T48.905A-S Adverse effect of unspecified agents primarily acting on the respiratory system, initial encounter
T48.995A-S Adverse effect of other agents primarily acting on the respiratory system, initial encounter
T49.0X5A-S Adverse effect of local antifungal, anti-infective and anti-inflammatory drugs, initial encounter
T49.1X5A-S Adverse effect of antipruritics, initial encounter
T49.2X5A-S Adverse effect of local astringents and local detergents, initial encounter
T49.3X5A-S Adverse effect of emollients, demulcents and protectants, initial encounter
T49.4X5A-S Adverse effect of keratolytics, keratoplastics, and other hair treatment drugs and preparations, initial encounter
T49.5X5A-S Adverse effect of ophthalmological drugs and preparations, initial encounter
T49.6X5A-S Adverse effect of otorhinolaryngological drugs and preparations, initial encounter
T49.7X5A-S Adverse effect of dental drugs, topically applied, initial encounter
T49.8X5A-S Adverse effect of other topical agents, initial encounter
T49.95XA-S Adverse effect of unspecified topical agent, initial encounter
T50.0X5A-S Adverse effect of mineralocorticoids and their antagonists, initial encounter
T50.1X5A-S Adverse effect of loop [high-ceiling] diuretics, initial encounter
T50.2X5A-S Adverse effect of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, initial encounter
T50.3X5A-S Adverse effect of electrolytic, caloric and water-balance agents, initial encounter
T50.4X5A-S Adverse effect of drugs affecting uric acid metabolism, initial encounter
T50.5X5A-S Adverse effect of appetite depressants, initial encounter
T50.6X5A-S Adverse effect of antidotes and chelating agents, initial encounter
T50.7X5A-S Adverse effect of analeptics and opioid receptor antagonists, initial encounter
T50.8X5A-S Adverse effect of diagnostic agents, initial encounter
T50.995A-S Adverse effect of other drugs, medicaments and biological substances, initial encounter
T50.A15A-S Adverse effect of pertussis vaccine, including combinations with a pertussis component, initial encounter
T50.A25A-S Adverse effect of mixed bacterial vaccines without a pertussis component, initial encounter
T50.A95A-S Adverse effect of other bacterial vaccines, initial encounter
T50.B15A-S Adverse effect of smallpox vaccines, initial encounter
T50.B95A-S Adverse effect of other viral vaccines, initial encounter
T50.Z15A-S Adverse effect of immunoglobulin, initial encounter
T50.Z95A-S Adverse effect of other vaccines and biological substances, initial encounter
T79.4XXA-S Traumatic shock, initial encounter
T81.10XA-T81.19XS Postprocedural shock unspecified, initial encounter
*Z48.22 Encounter for aftercare following kidney transplant
Magnesium.3 A/B

*Z48.23  Encounter for aftercare following liver transplant
Z49.31  Encounter for adequacy testing for hemodialysis
Z49.32  Encounter for adequacy testing for peritoneal dialysis
Z51.11  Encounter for antineoplastic chemotherapy
*Z79.3  Long term (current) use of hormonal contraceptives
*Z79.891 Long term (current) use of opiate analgesic
*Z79.899 Other long term (current) drug therapy
*Z94.0  Kidney transplant status
*Z94.4  Liver transplant status

*Diagnosis codes Z48.22, Z48.23, Z79.3, Z79.891, Z79.899, Z94.0 and Z94.4 should not be billed as the primary diagnosis.

Note: Renal dialysis facilities (72X) should report a diagnosis code of N18.6 for submission of claims.

Diagnoses that Support Medical Necessity
N/A

ICD-10 Codes that DO NOT Support Medical Necessity
N/A

Diagnoses that DO NOT Support Medical Necessity
N/A

Associated Information

Documentation Requirements

Medical record documentation (i.e., office notes/progress notes) maintained by the ordering/referring physician must indicate the medical necessity for performing the test. Additionally, a copy of the test results should be maintained in the medical records.

If the provider of the service is other than the ordering/referring physician, that provider must maintain hard copy documentation of test results and interpretation, along with copies of the ordering/referring physician’s order for the study. The physician must state the clinical indication/medical necessity for the study in the order for the test.

Utilization Guidelines

It is expected that these services would be performed as indicated by current medical literature and/or standards of practice. When services are performed in excess of established parameters, they may be subject to review for medical necessity.

Sources of Information and Basis for Decision

First Coast Service Options, Inc. reference LCD number(s) – L28924, L29217, L29446


Magnesium.3 A/B


Noble, John (Ed). (2001) Textbook of Primary Care Medicine (3rd ed.) St. Louis, MO: Mosby. This source used provide knowledge of the metabolic characteristics of magnesium, the pathophysiology of magnesium deficiency and its management.


Start Date of Comment Period

N/A

End Date of Comment Period

N/A

Start Date of Notice Period

N/A

Revision History

Revision History Number: R3

Revision Number: 3
Publication: September 2017 Connection
LCR A/B2017-038

Explanation of Revision: Based on CR 10153 (Annual 2018 ICD-10-CM Update) the LCD was revised. Added ICD-10-CM diagnosis codes E11.10 – E11.11,. The effective date of this revision is based on date of service.

Revision History Number: R2

Revision Number: 2
Publication: June 2017 Connection
LCR A/B2017-023

Explanation of Revision: Based on CR 8776, the following verbiage was removed from the “CPT/HCPCS Codes” section of the LCD: “Per CR 8572, beginning in CY 2014, payment for most laboratory tests (except for molecular pathology tests) will be packaged under the OPPS, therefore the clinical laboratory tests listed below, for TOB 13X (outpatient hospital), are packaged in this setting.” The effective date of this revision is for claims processed on or after 05/12/2017, for dates of service on or after 01/01/2014.

Revision History Number: R1

Revision Number: 1
Publication: October 2016 Connection
LCR A/B2016-097

Explanation of Revision: Based on CR 9677 (Annual 2017 ICD-10-CM Update) the LCD was revised to add ICD-10-CM diagnosis code range K52.831- K52.839 and ICD-10-CM diagnosis code M62.84. The ICD-10-CM diagnosis code K52.2 and diagnosis code range K85.0-K87 were deleted and replaced with ICD-10-CM code ranges K52.21-K52.29 and K85.00-K87. In addition, descriptors were revised for ICD-10-CM diagnosis codes P03.810-P03.89. The effective date of this revision is based on date of service.
Magnesium.3 A/B

**Revision Number:** Original

This LCD replaces all previous LCD versions (refer to “Sources of Information and Basis for Decision” section of the LCD) and publications on this subject to comply with ICD-10-CM based on Change Request 8112. The effective date of this LCD is based on date of service.

**Related Documents**

N/A

**LCD Attachments**

Coding Guidelines

---

Document formatted: 09/05/2017 (RC/NM/dc)